The Psychedelic Promise: A Second Win for Definium's LSD Treatment The world of psychedelic medicine is abuzz with excitement following Definium Therapeutics' latest breakthrough in treating generalized anxiety disorder.
For the second time, the company's LSD based medication has delivered a positive Phase 3 readout, solidifying its position as a leading contender in this emerging field. A Tipping Point for Psychedelic Medicine?
The success of Definium's DT120 treatment is significant because it reinforces a crucial aspect of psychedelic medicine: the notion that a single dose of a classic psychedelic can produce lasting improvements in serious mental health conditions.